Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook

Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.
FiercePharma

Merck's Keytruda dealt another blow in prostate cancer but readies new challenge to AZ's Imfinzi

In a split showing for cancer powerhouse Merck, its immunotherapy Keytruda continued a losing streak in prostate cancer but chalked up a win to pressure an industry-first approval by AstraZeneca.
Business Insider

Buy Rating Affirmed on Merck’s Promising Oncology Pipeline and Keytruda’s Commercial Success

Goldman Sachs analyst Chris Shibutani has reiterated their bullish stance on MRK stock, giving a Buy rating today. Chris Shibutani has given his Buy rating due to a combination of factors surrounding ...
Nasdaq

FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...
Investing

Formycon shares jump on first commercial agreement for Keytruda biosimilar

Investing.com -- Formycon shares jumped more than 6% on Thursday after the company announced its first commercial agreement for FYB206, its biosimilar candidate to Merck’s Keytruda. The deal covers ...